Vimarsana
Biggest News Aggregation in the World

Page 7 - Capital Return News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Capital Return. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Capital Return Today - Breaking & Trending Today

Argo Files Investor Presentation Highlighting Transformation into a Leading U.S. Specialty Insurer and Comprehensive, Ongoing Strategic Alternatives Process - Vimarsana News

Argo Files Investor Presentation Highlighting Transformation into a Leading U.S. Specialty Insurer and Comprehensive, Ongoing Strategic Alternatives Process

Strategic Repositioning that Began in Late 2019 Has Created Stronger Growth Platform and Optimized Business Mix Refreshed Board, Which Includes Company’s Largest Shareholder, Has Right Skills... | November 18, 2022

Capital Returns Releases Investor Presentation Describing the Compelling Case for Board Change at Argo Group - Vimarsana News

Capital Returns Releases Investor Presentation Describing the Compelling Case for Board Change at Argo Group

/PRNewswire/ -- Capital Returns Management, LLC (together with its affiliates, "Capital Returns," "we" or "us"), one of the largest shareholders among actively...

Investegate |Zegona Comm PLC Announcements | Zegona Comm PLC: MANAGEMENT INCREASES SHAREHOLDING IN ZEGONA TO 29% - Vimarsana News

Investegate |Zegona Comm PLC Announcements | Zegona Comm PLC: MANAGEMENT INCREASES SHAREHOLDING IN ZEGONA TO 29%

Investegate announcements from Zegona Comm PLC, MANAGEMENT INCREASES SHAREHOLDING IN ZEGONA TO 29%

Argo burns through more than half of $75mn Enstar loss corridor - Vimarsana News

Argo burns through more than half of $75mn Enstar loss corridor

Argo has recognized $37.7mn of prior year development (PYD) in the first nine months of 2022, which falls within the retained loss corridor of $75mn in the loss portfolio transfer (LPT) deal the specialty insurer struck with Enstar in Q2 for its US insurance back-book.

Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer - Vimarsana News

Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer

Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35%...